Amerigroup
An Anthem Company

Provider update

A message for providers: Prior Preterm Pregnancy Program

To support your efforts in preventing preterm delivery in high-risk pregnant women, Amerigroup Community Care has a program to ensure providers are aware of members who may benefit from administration of 17 alpha-hydroxyprogesterone caproate (17P). You will receive an alert listing members on your panel identified through our high-risk screening survey as potential candidates for 17P.

If you wish to prescribe 17P for your patient, we offer the following guidance on how you may obtain 17P for delivery and administration:

Prior authorization (PA): 17P requires PA; please complete the attached *Amerigroup Pharmacy Prior Authorization Form* and fax it to 1-800-359-5781 or call 1-800-454-3730. Starting April 1, 2018, fax forms to 1-844-509-9865.
Documentation: Include pertinent clinical documentation with the *Amerigroup Pharmacy Prior Authorization Form.* The medical necessity criteria, which can be found in the *Clinical Utilization Management (UM) Guideline CG-Drug-19* located on the provider website, includes the following statement:

- Weekly injections of 17P between 16 and 36 weeks of gestation are considered medically necessary in pregnant women who meet all of the following criteria:
    - Singleton pregnancy
    - Absence of preterm labor within the current pregnancy
    - A prior history of a preterm delivery before 37 weeks gestation due to either spontaneous preterm labor or premature rupture of membranes

Prescription: Once PA is approved, fax the prescription with the PA approval number to Accredo Specialty Pharmacy at 1-800-824-2642 or call 1-844-433-4876. Prior to dispensing the medication, Accredo will reach out to your patient via phone to verify member information. Please advise your patient to expect a phone call from Accredo.
Home health (when applicable): If home health services are required for administration of 17P, a separate prior authorization for this service is required; please contact Provider Services at 1-800-454-3730 for home health authorization requests. Refer to the criteria listed in *Clinical UM Guideline CG-MED-23* located on the provider website.

Preterm birth (delivery before 37 weeks and zero/seven days of gestation) is a leading cause of infant morbidity and mortality in the United States. For women who have had a spontaneous preterm delivery, the risk for preterm delivery in subsequent pregnancies is 1.5-2 times higher. For pregnant women with a singleton pregnancy and a history of spontaneous preterm delivery, 17P can reduce the risk of preterm birth by approximately 30 percent. The U.S. Food and Drug Administration approved hydroxyprogesterone caproate injections to reduce the risk of preterm delivery in pregnant women with a history of prior preterm birth. As with any drug, there are risks which may outweigh these benefits.

Attachment: *Amerigroup Prior Authorization Form*

What if I need assistance?
If you have questions about this communication, received this fax in error or need assistance with any other item, contact your local Provider Relations representative at 1-800-454-3730.